A phase i study evaluating tolerability, pharmacokinetics, and preliminary efficacy of l-menthol in upper gastrointestinal endoscopy

N. Hiki, M. Kaminishi, T. Hasunuma, M. Nakamura, S. Nomura, Naohisa Yahagi, H. Tajiri, H. Suzuki

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Peppermint oil has been shown to relax gastrointestinal smooth muscle. In this randomized, placebo-controlled study, an L-menthol preparation, NPO-11, was assessed for tolerability and pharmacokinetics (PK) during gastrointestinal endoscopy. Single doses of NPO-11, as high as 320mg, were well tolerated. NPO-11 was rapidly absorbed, with peak concentrations reached within 1h after administration. Approximately 70% of the administered L-menthol and its metabolites were excreted in the urine, and this amount fluctuated with no change in the dose. The principal metabolite identified in plasma and urine was menthol glucuronide. The other metabolites include mono-or di-hydroxylated menthol derivatives, most of which are excreted, in part, as glucuronic acid conjugates. The pharmacokinetic data indicated that when NPO-11 is sprayed directly onto the gastric mucosa, it is rapidly metabolized to glucuronic acid conjugates that are excreted in urine. The findings from this study provide new data on the safety and PK of NPO-11 and support further trials.

Original languageEnglish
Pages (from-to)221-228
Number of pages8
JournalClinical Pharmacology and Therapeutics
Volume90
Issue number2
DOIs
Publication statusPublished - 2011 Aug

Fingerprint

Menthol
Gastrointestinal Endoscopy
Glucuronic Acid
Pharmacokinetics
Urine
Gastric Mucosa
Smooth Muscle
Placebos
Safety

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

A phase i study evaluating tolerability, pharmacokinetics, and preliminary efficacy of l-menthol in upper gastrointestinal endoscopy. / Hiki, N.; Kaminishi, M.; Hasunuma, T.; Nakamura, M.; Nomura, S.; Yahagi, Naohisa; Tajiri, H.; Suzuki, H.

In: Clinical Pharmacology and Therapeutics, Vol. 90, No. 2, 08.2011, p. 221-228.

Research output: Contribution to journalArticle

Hiki, N. ; Kaminishi, M. ; Hasunuma, T. ; Nakamura, M. ; Nomura, S. ; Yahagi, Naohisa ; Tajiri, H. ; Suzuki, H. / A phase i study evaluating tolerability, pharmacokinetics, and preliminary efficacy of l-menthol in upper gastrointestinal endoscopy. In: Clinical Pharmacology and Therapeutics. 2011 ; Vol. 90, No. 2. pp. 221-228.
@article{99b35308c5be486085b21d221352634e,
title = "A phase i study evaluating tolerability, pharmacokinetics, and preliminary efficacy of l-menthol in upper gastrointestinal endoscopy",
abstract = "Peppermint oil has been shown to relax gastrointestinal smooth muscle. In this randomized, placebo-controlled study, an L-menthol preparation, NPO-11, was assessed for tolerability and pharmacokinetics (PK) during gastrointestinal endoscopy. Single doses of NPO-11, as high as 320mg, were well tolerated. NPO-11 was rapidly absorbed, with peak concentrations reached within 1h after administration. Approximately 70{\%} of the administered L-menthol and its metabolites were excreted in the urine, and this amount fluctuated with no change in the dose. The principal metabolite identified in plasma and urine was menthol glucuronide. The other metabolites include mono-or di-hydroxylated menthol derivatives, most of which are excreted, in part, as glucuronic acid conjugates. The pharmacokinetic data indicated that when NPO-11 is sprayed directly onto the gastric mucosa, it is rapidly metabolized to glucuronic acid conjugates that are excreted in urine. The findings from this study provide new data on the safety and PK of NPO-11 and support further trials.",
author = "N. Hiki and M. Kaminishi and T. Hasunuma and M. Nakamura and S. Nomura and Naohisa Yahagi and H. Tajiri and H. Suzuki",
year = "2011",
month = "8",
doi = "10.1038/clpt.2011.110",
language = "English",
volume = "90",
pages = "221--228",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - A phase i study evaluating tolerability, pharmacokinetics, and preliminary efficacy of l-menthol in upper gastrointestinal endoscopy

AU - Hiki, N.

AU - Kaminishi, M.

AU - Hasunuma, T.

AU - Nakamura, M.

AU - Nomura, S.

AU - Yahagi, Naohisa

AU - Tajiri, H.

AU - Suzuki, H.

PY - 2011/8

Y1 - 2011/8

N2 - Peppermint oil has been shown to relax gastrointestinal smooth muscle. In this randomized, placebo-controlled study, an L-menthol preparation, NPO-11, was assessed for tolerability and pharmacokinetics (PK) during gastrointestinal endoscopy. Single doses of NPO-11, as high as 320mg, were well tolerated. NPO-11 was rapidly absorbed, with peak concentrations reached within 1h after administration. Approximately 70% of the administered L-menthol and its metabolites were excreted in the urine, and this amount fluctuated with no change in the dose. The principal metabolite identified in plasma and urine was menthol glucuronide. The other metabolites include mono-or di-hydroxylated menthol derivatives, most of which are excreted, in part, as glucuronic acid conjugates. The pharmacokinetic data indicated that when NPO-11 is sprayed directly onto the gastric mucosa, it is rapidly metabolized to glucuronic acid conjugates that are excreted in urine. The findings from this study provide new data on the safety and PK of NPO-11 and support further trials.

AB - Peppermint oil has been shown to relax gastrointestinal smooth muscle. In this randomized, placebo-controlled study, an L-menthol preparation, NPO-11, was assessed for tolerability and pharmacokinetics (PK) during gastrointestinal endoscopy. Single doses of NPO-11, as high as 320mg, were well tolerated. NPO-11 was rapidly absorbed, with peak concentrations reached within 1h after administration. Approximately 70% of the administered L-menthol and its metabolites were excreted in the urine, and this amount fluctuated with no change in the dose. The principal metabolite identified in plasma and urine was menthol glucuronide. The other metabolites include mono-or di-hydroxylated menthol derivatives, most of which are excreted, in part, as glucuronic acid conjugates. The pharmacokinetic data indicated that when NPO-11 is sprayed directly onto the gastric mucosa, it is rapidly metabolized to glucuronic acid conjugates that are excreted in urine. The findings from this study provide new data on the safety and PK of NPO-11 and support further trials.

UR - http://www.scopus.com/inward/record.url?scp=79960611229&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960611229&partnerID=8YFLogxK

U2 - 10.1038/clpt.2011.110

DO - 10.1038/clpt.2011.110

M3 - Article

VL - 90

SP - 221

EP - 228

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 2

ER -